Bharat Biotech has teamed up with Alopexx Inc to co-develop and market the broad-spectrum antimicrobial vaccine AV0328 in India and other low-income areas. The vaccine targets poly N-acetyl glucosamine found on various pathogens. Pre-clinical studies showed its effectiveness against over 15 pathogens, and a phase I trial confirmed its safety.
Related Posts
Over $310 million linked to Adani Group in Swiss banks frozen for probe: Hindenburg
The Adani Group has denied allegations from Hindenburg Research that Swiss authorities froze over $310 million across six bank accounts amid a money laundering investigation. […]
Aurobindo Pharma arm CuraTeQ gets positive EMA opinion for biosimilar Zefylti
Aurobindo Pharma’s subsidiary, CuraTeQ Biologics, received a positive CHMP opinion for its filgrastim biosimilar, Zefylti, intended to treat neutropenia and mobilize peripheral progenitor cells. Zefylti […]